Femasys (NASDAQ:FEMY) PT Raised to $12.00

Femasys (NASDAQ:FEMYGet Free Report) had its target price increased by stock analysts at HC Wainwright from $10.00 to $12.00 in a report released on Monday, Benzinga reports. The brokerage currently has a “buy” rating on the stock. HC Wainwright also issued estimates for Femasys’ Q1 2024 earnings at ($0.22) EPS, Q2 2024 earnings at ($0.24) EPS, Q3 2024 earnings at ($0.21) EPS, Q4 2024 earnings at ($0.22) EPS and FY2028 earnings at ($0.14) EPS.

A number of other brokerages also recently commented on FEMY. Chardan Capital reaffirmed a “buy” rating and issued a $12.00 price objective on shares of Femasys in a research report on Thursday, March 21st. Jonestrading lifted their price objective on Femasys from $7.00 to $10.00 and gave the company a “buy” rating in a research report on Wednesday, March 20th.

View Our Latest Research Report on FEMY

Femasys Price Performance

Shares of NASDAQ:FEMY opened at $1.74 on Monday. The business’s fifty day moving average price is $1.45 and its two-hundred day moving average price is $1.24. The stock has a market cap of $37.67 million, a PE ratio of -1.89 and a beta of -3.00. The company has a debt-to-equity ratio of 0.01, a quick ratio of 4.40 and a current ratio of 4.68. Femasys has a one year low of $0.25 and a one year high of $4.75.

Femasys (NASDAQ:FEMYGet Free Report) last announced its earnings results on Thursday, March 28th. The company reported ($0.19) EPS for the quarter, meeting analysts’ consensus estimates of ($0.19). The firm had revenue of $0.21 million for the quarter, compared to analysts’ expectations of $0.30 million. Femasys had a negative return on equity of 119.80% and a negative net margin of 1,329.10%. On average, analysts forecast that Femasys will post -0.74 EPS for the current fiscal year.

Institutional Investors Weigh In On Femasys

A number of hedge funds and other institutional investors have recently made changes to their positions in FEMY. Vanguard Group Inc. acquired a new position in shares of Femasys during the first quarter worth about $269,000. Barclays PLC acquired a new position in shares of Femasys during the third quarter worth about $295,000. Northern Trust Corp acquired a new position in shares of Femasys during the fourth quarter worth about $77,000. Schonfeld Strategic Advisors LLC acquired a new position in shares of Femasys during the third quarter worth about $199,000. Finally, UBS Group AG lifted its stake in shares of Femasys by 6,394.8% during the first quarter. UBS Group AG now owns 66,702 shares of the company’s stock worth $151,000 after purchasing an additional 65,675 shares in the last quarter. Hedge funds and other institutional investors own 65.27% of the company’s stock.

Femasys Company Profile

(Get Free Report)

Femasys Inc, a biomedical company, develops novel solutions for women's healthcare market in the United States and internationally. The company provides FemVue saline-air device, a contrast-generating product in the United States, Canada, Japan, and Hong Kong; FemCath, a cornual balloon catheter, a single intrauterine directional delivery product that allows for selective evaluation of an individual fallopian tube; and FemCerv, a biopsy device for endocervical curettage, which can be used to sample cervical cells and tissue circumferentially with sample containment within the device to minimize contamination.

Recommended Stories

Receive News & Ratings for Femasys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Femasys and related companies with MarketBeat.com's FREE daily email newsletter.